These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 23172264)

  • 1. Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection.
    Gatti DC; Cha A
    Am J Health Syst Pharm; 2012 Dec; 69(23):2062-5. PubMed ID: 23172264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
    Peterson D; Van Ermen A
    Am J Health Syst Pharm; 2017 Jun; 74(12):888-892. PubMed ID: 28596225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telaprevir: an oral protease inhibitor for hepatitis C virus infection.
    Kim JJ; Culley CM; Mohammad RA
    Am J Health Syst Pharm; 2012 Jan; 69(1):19-33. PubMed ID: 22180548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Britnell SR; Willets AE; Vanderman AJ; Woodard CL; Britt RB
    Pharmacotherapy; 2016 Nov; 36(11):1173-1179. PubMed ID: 27716978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telaprevir for previously treated chronic HCV infection.
    McHutchison JG; Manns MP; Muir AJ; Terrault NA; Jacobson IM; Afdhal NH; Heathcote EJ; Zeuzem S; Reesink HW; Garg J; Bsharat M; George S; Kauffman RS; Adda N; Di Bisceglie AM;
    N Engl J Med; 2010 Apr; 362(14):1292-303. PubMed ID: 20375406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial.
    Reddy KR; Zeuzem S; Zoulim F; Weiland O; Horban A; Stanciu C; Villamil FG; Andreone P; George J; Dammers E; Fu M; Kurland D; Lenz O; Ouwerkerk-Mahadevan S; Verbinnen T; Scott J; Jessner W
    Lancet Infect Dis; 2015 Jan; 15(1):27-35. PubMed ID: 25482330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.
    Forestier N; Reesink HW; Weegink CJ; McNair L; Kieffer TL; Chu HM; Purdy S; Jansen PL; Zeuzem S
    Hepatology; 2007 Sep; 46(3):640-8. PubMed ID: 17879366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible warfarin resistance due to interaction with ascorbic acid: case report and literature review.
    Sattar A; Willman JE; Kolluri R
    Am J Health Syst Pharm; 2013 May; 70(9):782-6. PubMed ID: 23592361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potential interaction between warfarin and atovaquone.
    Hidalgo K; Lyles A; Dean SR
    Ann Pharmacother; 2011 Jan; 45(1):e3. PubMed ID: 21189363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.
    Buti M; Agarwal K; Horsmans Y; Sievert W; Janczewska E; Zeuzem S; Nyberg L; Brown RS; Hézode C; Rizzetto M; Paraná R; De Meyer S; De Masi R; Luo D; Bertelsen K; Witek J
    Gastroenterology; 2014 Mar; 146(3):744-753.e3. PubMed ID: 24316262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Telaprevir for previously untreated chronic hepatitis C virus infection.
    Jacobson IM; McHutchison JG; Dusheiko G; Di Bisceglie AM; Reddy KR; Bzowej NH; Marcellin P; Muir AJ; Ferenci P; Flisiak R; George J; Rizzetto M; Shouval D; Sola R; Terg RA; Yoshida EM; Adda N; Bengtsson L; Sankoh AJ; Kieffer TL; George S; Kauffman RS; Zeuzem S;
    N Engl J Med; 2011 Jun; 364(25):2405-16. PubMed ID: 21696307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
    McHutchison JG; Everson GT; Gordon SC; Jacobson IM; Sulkowski M; Kauffman R; McNair L; Alam J; Muir AJ;
    N Engl J Med; 2009 Apr; 360(18):1827-38. PubMed ID: 19403902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moxifloxacin-acetaminophen-warfarin interaction during bacille Calmette-Guerin treatment for bladder cancer.
    Lee R; Wen A; Berube C
    Am J Health Syst Pharm; 2011 May; 68(9):814-7. PubMed ID: 21515865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated International Normalized Ratio in a patient concurrently using warfarin and vismodegib.
    Lim S; Houranieh J; Crawford R
    Am J Health Syst Pharm; 2014 Feb; 71(3):200-3. PubMed ID: 24429012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probable interaction between warfarin and bee pollen.
    Hurren KM; Lewis CL
    Am J Health Syst Pharm; 2010 Dec; 67(23):2034-7. PubMed ID: 21098375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A probable interaction between warfarin and the antiretroviral TRIO study regimen.
    Liedtke MD; Vanguri A; Rathbun RC
    Ann Pharmacother; 2012 Nov; 46(11):e34. PubMed ID: 23115227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.
    Rubin RA; Russo MW; Brown KA; Fontana RJ; Levitsky J; Vargas H; Yoshida EM; Brown RS
    Exp Clin Transplant; 2018 Apr; 16(2):182-190. PubMed ID: 27855589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients.
    Lawitz E; Rodriguez-Torres M; Muir AJ; Kieffer TL; McNair L; Khunvichai A; McHutchison JG
    J Hepatol; 2008 Aug; 49(2):163-9. PubMed ID: 18486984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.